DSM Capital Partners LLC Sells 81,763 Shares of Abbott Laboratories $ABT

DSM Capital Partners LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 9.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 772,348 shares of the healthcare product maker’s stock after selling 81,763 shares during the quarter. Abbott Laboratories comprises approximately 1.6% of DSM Capital Partners LLC’s portfolio, making the stock its 22nd biggest position. DSM Capital Partners LLC’s holdings in Abbott Laboratories were worth $105,047,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Conning Inc. increased its holdings in shares of Abbott Laboratories by 0.3% during the second quarter. Conning Inc. now owns 260,318 shares of the healthcare product maker’s stock valued at $35,406,000 after acquiring an additional 727 shares in the last quarter. Trust Co. of Toledo NA OH increased its holdings in shares of Abbott Laboratories by 0.7% during the second quarter. Trust Co. of Toledo NA OH now owns 74,008 shares of the healthcare product maker’s stock valued at $10,066,000 after acquiring an additional 495 shares in the last quarter. Eastern Bank increased its holdings in shares of Abbott Laboratories by 35.0% during the second quarter. Eastern Bank now owns 322,469 shares of the healthcare product maker’s stock valued at $43,859,000 after acquiring an additional 83,626 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of Abbott Laboratories by 4.2% during the second quarter. Aberdeen Group plc now owns 2,018,942 shares of the healthcare product maker’s stock valued at $272,880,000 after acquiring an additional 81,094 shares in the last quarter. Finally, First Fiduciary Investment Counsel Inc. increased its holdings in shares of Abbott Laboratories by 4.0% during the second quarter. First Fiduciary Investment Counsel Inc. now owns 3,926 shares of the healthcare product maker’s stock valued at $534,000 after acquiring an additional 150 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Morgan Stanley lifted their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. BTIG Research reduced their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Royal Bank Of Canada lifted their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Tuesday, July 15th. Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Finally, The Goldman Sachs Group lifted their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $146.17.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Trading Down 0.8%

Shares of NYSE:ABT opened at $132.30 on Friday. The stock has a market capitalization of $230.26 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.53 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The stock’s 50-day simple moving average is $132.54 and its two-hundred day simple moving average is $131.56. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the firm posted $1.14 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.